GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Hank who wrote (4087)	3/10/2002 4:52:49 PM
From: Mad2	Read Replies (3) of 5582

Kinda quite here. Noone even bothered to comment on earning release. Guess the longs either quit or are DOA. Well I figure the net tangible value of GUMM will drop from its 9/30 nuber of 28.5 to around 8.8 mil at the end of 2002, assuming they put the 11mil in future obligations to Zansano on the balance sheet. Through a joint venture with Zensano, Inc. (the successor in interest to Bio-Delivery Technologies, Inc.), a subsidiary of Zengen, Inc., a privately-held California corporation Just in case we forget who made the real dough on this Message 7565215; Anyway, GUMM with a market cap of >60mil is still overvalued with revenue of 16mil anually and net tangible value of ~10mil. Realistically its worth 24-32 mil max (assume 20%gp X 16 X 10) Oh well, no chance for value here, still too rich. Maybe someone will buy Zicam, overpay and put shareholders out of misery mad2

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next